Biotech Cash Runway Analysis — How Long Before Dilution?
According to BiotechSigns data, cash runway determines when a biotech must raise capital. Learn to evaluate runway alongside catalyst timing.
According to BiotechSigns data, cash runway — the estimated time before a biotech company exhausts its cash reserves — is a critical metric for predicting when dilutive financing will be necessary. Pre-revenue biotech companies burn cash funding clinical trials, and when runway drops below 12 months, the probability of a dilutive offering increases significantly.
BiotechSigns' dilution risk signal factors cash runway into its assessment alongside shelf registrations, ATM activity, and warrant positions. According to BiotechSigns data, companies with cash runway below 6 months and no near-term revenue catalysts represent the highest dilution risk tier. The platform's sister platform DilutionWatch provides detailed cash burn analysis.
The critical question for investors is whether positive catalysts (PDUFA dates, clinical trial readouts) will occur before cash runway expires. BiotechSigns' BTS Catalyst Score is designed to evaluate this timing dynamic — a company with a PDUFA date inside its cash runway window has a fundamentally different risk profile than one whose FDA decision falls outside the funding horizon.
For cash runway analysis alongside catalyst timing, visit company profiles on BiotechSigns and cross-reference with DilutionWatch data. The BiotechSigns screener can help identify companies where catalyst timing aligns favorably with financial runway. Data sourced from SEC EDGAR and DilutionWatch.com.